AG
PETX

Algert Global’s Aratana Therapeutics, Inc. PETX Stock Holding History

Algert Global’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-23,616
Closed -$221K – 429
2016
Q3 		$221K Buy
+23,616
New +$196K 0.06% 323

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Algert Global's PETX Position: Q4 2016 in Review

Algert Global sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 23,616 shares — an estimated $221K sold.

Algert Global first reported a position in PETX in Q3 2016 and held it in 1 quarter. The position peaked at $221K in Q3 2016. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • Algert Global reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Algert Global sold 23,616 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $221K.
  • Algert Global first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Algert Global's Aratana Therapeutics, Inc. position peaked at $221K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on Algert Global's 13F filing for Q4 2016, filed 26 Jan 2017.